ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Sermion®:Pfizer AG
Vollst. FachinformationDDDDrucken 
Gal.Form/Ther.Gr.Zusammens.Eigensch.Pharm.kinetikInd./Anw.mögl.Dos./Anw.Anw.einschr.Unerw.Wirkungen
Interakt.Überdos.Sonstige H.Swissmedic-Nr.Stand d. Info. 
C04AE02 - NicergolineATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C04 - Peripheral Vasodilators
 
C04A - Peripheral Vasodilators

This group comprises plain and combined preparations used in the treatment of cerebrovascular or peripheral circulatory disorders.
Combinations with Antihypertensives, see C02 - Antihypertensives.
Combinations with vasodilators used in cardiac diseases, see C01DA.

The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.

C04AE - Ergot Alkaloids

Includes combinations with other peripheral vasodilators.
Combinations with calcium channel blockers are classified in C08CA.
Combinations of cinnarizine and dihydroergocristine are classified in N07CA52.
See also G02AB and N02CA.

C04AE02 - Nicergoline
2025 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home